DISRUPTIDE
LIVE

Serial Number

99834893

Owner

Rime Therapeutics Inc.

Attorney

Karen K. Won

Filing Date

May 20, 2026

Add to watchlist:

No watchlists yet
View on USPTO

DISRUPTIDE Trademark

Serial Number: 99834893

DISRUPTIDE is a trademark filed by Rime Therapeutics Inc. on May 20, 2026. The trademark is classified under Class 1 (Chemicals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Rime Therapeutics Inc.

3 Place Ville-Marie, Suite 12350
Montréal, QC H3B 0E7 , CA

Entity Type: 03

Trademark Details

Filing Date

May 20, 2026

Registration Date

Not Registered

Goods & Services

chemical preparations and reagents, namely, peptide sequences and peptide probes for use in drug discovery and development; AI-designed peptide probes for use in drug discovery and development; live-cell functional assays and drug screen assays involving engineered peptide probes, for research purposes; engineered peptide probes for live-cell phenotypic screening, intracellular target identification and validation, generation of molecular chemical profiles of function hits at defined target sites, and peptide-based drug discovery and development; genetically-deliverable peptide sequences and peptide probes for preserving peptide conformation, minimizing steric interference, and enhancing peptide intracellular stability

Drug and drug target discovery services; Design, development, and engineering of peptide sequences and peptide probes for use in drug discovery and development; Medical scientific research, analysis, and testing, namely, using engineered peptide probes in live-cell phenotypic screening, intracellular target identification and validation, generation of molecular chemical profiles of function hits at defined target sites, and peptide-based drug discovery and development; Using AI-designed peptide probes to conduct research, testing, and analysis of peptide-target pairs as molecular blueprints for developing small molecule inhibitors; Providing medical scientific information, advisory, and consultancy services in the fields of peptides, peptide-based drug discovery and development, and phenotypic drug screening

Filing History

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 31, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
May 20, 2026 MAFR
NEW APPLICATION ENTERED
May 20, 2026 NWAP